New Therapeutic Agents in Thrombosis and Thrombolysis

As the number of patients with thrombosis and thrombolysis increases, there is a critical need for clinicians to learn the latest scientific discoveries and treatment options. This timely Third Edition is a comprehensive text for cardiologists, hematologists, and pharmacologists in need of a resource on current agent development technology for treating cardiovascular and thromboembolic diseases.New to the Third Edition:a thorough examination of all the agents involved in treating thrombosischapters on biomarkers, testing, and pharmacogenomicskey topics, including new targets for antithrombotics, the development of novel classes of platelet inhibitors, new thrombolytic therapies, and evolving clinical uses of thrombolytics for ischemic stroke and venous thrombosisthe hemostatic and thrombotic pathwaysTable of ContentPreface. Part I. Overview. Overview of Hemostasis and Fibrinolysis. Overview of Platelet-dependent Thrombosis. Design Issues in Clinical Trials of Thrombolytic and Antithrombotic Agents. Pharmacogenomics of Anticoagulation. Pharmacogenomics of Antithrombotics. The Role of Biomarkers in the Development of Antithrombotics and Fibrinolytics. The Role of Platelet Function Testing in the Development of Platelet Inhibitors. The Role of Proteomics and Transcriptomics in the Development of Antithrombotics. Part II: New Heparins, Thrombin Inhibitors, and Antithrombotics. Overview of New Anticoagulant Drugs. Low-Molecular-Weight Heparins in Acute Coronary Syndromes. Low-Molecular-Weight Heparin Use in Pregnancy. Antithrombotic Therapy and Cancer. Prophylaxis with Low-Molecular-Weight Heparin in the Treatment of Venous Thromboembolism. Low-Molecular-Weight Heparin in the Pediatric Population. New Indications for Low-Molecular-Weight Heparins. Drugs Indicated for HIT. Hirudin for Acute Coronary Syndromes. Oral-Direct Thrombin Inhibitors: dibigatran and ximelagatran. Oral direct Factor Xa inhibitors: including rivaroxaban, apixaban, YM-150, Du-176b. Orally Active Heparin. Tissue Factor Pathway Inhibitor: (Potential Implications in the Treatment of Cardiovascular Disorders). Modulation of the Protein C Pathway as a Therapy for Thrombosis. Soluble Thrombomodulin. Activated Factor X Agonists and the Development of Synthetic Pentasaccharides: Fondaparinux and idraparinux. Factor IXa Inhibitors. Aptamers. Part III: New Antiplatelet Agents. Overview: Antiplatelet Therapy. Intravenous Glyoprotein IIb/IIIa Receptor Antagonists. Procoagulant Activities of Glycoprotein IIb/IIIa Receptor Blockers. Inhibitors of Platelet Adhesion:vWF-GP1b/IX and Collagen-GPVI inhibitors. Thienopyridines: Ticlopidine and Clopidogrel. New Thienopyridines; reversible P2Y(12) antagonists, cangrelor and AZD6140. Oral Antiplatelet Therapies Beyond Aspirin and Thienopyridines. PAR1 Inhibitors. NO donors as Platelet Inhibitors. Part IV: New Thrombolytic Agents and Indications. Overview of Established and New Thrombolytics. Thrombolysis of Deep Vein Thrombosis. Thrombolysis for Pulmonary Embolism. Thrombolysis for Ischemic Stroke. Thrombolysis for Acute Myocardial Infarction. Thrombolysis and Ultrasound. Epilogue: The Management of Thrombotic and Cardiovascular Disorders in the 21st Century.Review Quote"…Full of important information… is a definite addition to the medical literature." —Doody’s Reviews (for the Second Edition)Biographical NoteJane E. Freedman, Joseph Loscalzo